Clinical trials: Myeloma Multiple
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and the best dose of pomalidomide when given together with dexamethasone and filgrastim-sndz and to see how well they work in treating patients with multiple myeloma that has…
- Conditions
- Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01946152
- Testing
- Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma…
- Trial name
- NCT02002598
- Testing
- Bendamustine, Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Suzanne Lentzsch, MD
Multiple Myeloma
A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
The study evaluated the safety of Lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone…
- Trial name
- NCT00622336
- Testing
- CC-5013, Lenalidomide
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 330 people
- Sponsor
- Celgene
Multiple Myeloma
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
The purpose of this research study is to define the time a molecule in the participants bones called NTX begins to rise after receiving treatment with bisphosphonates.
- Trial name
- NCT00577642
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
This is a continuation of a pilot study which is now regarded as a phase II trial with a plan to enroll an additional 40 patients (20 related and 20 unrelated donor transplants) with hematological malignancy assessing the safety…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00571662
- Testing
- Pentostatin, Total-body irradiation (TBI), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Nebraska
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study to explore the combination of Revlimid®, oral cyclophosphamide and prednisone (RCP) in patients with newly diagnosed multiple myeloma.
- Trial name
- NCT00540644
- Testing
- lenalidomide (Revlimid®), Cyclophosphamide, Prednisone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Attaya Suvannasankha
Relapsed or Refractory Multiple Myeloma
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.
- Trial name
- NCT01866293
- Testing
- Cabozantinib (XL184)
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Myeloma
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Background: Recent studies have shown that smoldering multiple myeloma has a high risk of progressing to multiple myeloma, an aggressive type of bone marrow cancer, within 5 years of diagnosis.
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT01248455
- Testing
- (Anti-KIR)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy…
- Trial name
- NCT04140162
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Michigan Rogel Cancer Center
Leukemia, Lymphoma
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as melphalan and fludarabine, and a monoclonal antibody, such as alemtuzumab, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00027560
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Mucositis, Multiple Myeloma
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation
Chemotherapy-induced oral mucositis is the inflammation of the oral mucous membranes, which are tissues that line the mouth. Oral mucositis is caused when chemotherapy attacks and kills the rapidly-dividing cells in the oral…
- Trial name
- NCT01066624
- Testing
- 0.9% Sodium Chloride irrigation solution, Cryotherapy (ice chips), Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Relapsed Multiple Myeloma
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
- Trial name
- NCT01080391
- Testing
- Dexamethasone, Lenalidomide, Carfilzomib
- Where
- 127 sites in United States, Austria and 18 more
- Volunteers
- 792 people
- Sponsor
- Amgen
Multiple Myeloma
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma.
- Trial name
- NCT02863991
- Testing
- ONC201, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Myeloma
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
The primary objectives of this study included the following: Phase 1b: To establish the maximum tolerated dose (MTD) of oprozomib given in combination with lenalidomide and dexamethasone (ORd) or with cyclophosphamide and…
- Trial name
- NCT01881789
- Testing
- Oprozomib, Lenalidomide, Dexamethasone
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation